Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multitrait Polygenic Risk Score for Open-Angle Glaucoma Stratifies Risk of Pigmentary Glaucoma in Pigment Dispersion Syndrome.

Ophthalmology. Glaucoma·2025
Same author

Effect of Acetazolamide on Intraocular Pressure After Uneventful Phacoemulsification Using an Anterior Chamber Maintainer.

Vision (Basel, Switzerland)·2025
Same author

Comparative Evaluation of Classic Mechanical and Digital Goldmann Applanation Tonometers.

Diagnostics (Basel, Switzerland)·2025
Same author

A Multitrait Open-Angle Glaucoma Polygenic Risk Score Stratifies Risk of Glaucoma Diagnosis and Severity in Eyes with Pseudoexfoliation.

Ophthalmology·2025
Same author

Flow-Adjusted Trabeculectomy.

Journal of clinical medicine·2024
Same author

Dr. Google will see you now: But will he make you sick?

Taiwan journal of ophthalmology·2024
Same journal

Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia.

The open ophthalmology journal·2018
Same journal

Maximising Refractive Outcomes with an Extended Depth of Focus IOL.

The open ophthalmology journal·2018
Same journal

Refractive Error among Male Primary School Students in Jazan, Saudi Arabia: Prevalence and Associated Factors.

The open ophthalmology journal·2018
Same journal

Outcomes of Wavefront-Optimized Laser-Assisted <i>In-Situ</i> Keratomileusis and Photorefractive Keratectomy for correction of Myopia and Myopic Astigmatism over One Year Follow-Up.

The open ophthalmology journal·2018
Same journal

Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis.

The open ophthalmology journal·2018
Same journal

A New User-Friendly and Affordable Method in Descemet Stripping Endothelial Keratoplasty.

The open ophthalmology journal·2018
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Stepping up glaucoma management: when and how?

Ivan Goldberg1

  • 1Department of Ophthalmology, University of Sydney, Australia.

The Open Ophthalmology Journal
|October 17, 2009
PubMed
Summary
This summary is machine-generated.

Glaucoma management focuses on reducing intraocular pressure to prevent vision loss. Treatment is intensified when disease progression or risk factors increase, ensuring optimal patient outcomes.

Related Experiment Videos

Last Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Optometry
  • Nephrology

Background:

  • Glaucoma management aims to preserve visual function and quality of life.
  • Intraocular pressure (IOP) reduction is the primary strategy for halting glaucoma progression.
  • Treatment targets are individualized based on disease severity, risk factors, and patient characteristics.

Purpose of the Study:

  • To outline the criteria for stepping up glaucoma management.
  • To define when treatment intensification is necessary for glaucoma patients and suspects.
  • To emphasize the importance of regular monitoring in glaucoma care.

Main Methods:

  • Establishing individualized target intraocular pressure (IOP) levels.
  • Regularly reviewing patients to assess disease status and risk of progression.
  • Adjusting treatment regimens based on changes in disease activity or risk.

Main Results:

  • Glaucoma management requires stepping up when disease progression is evident or the risk of future damage increases.
  • Ophthalmologists assess disease stability and risk level at each review.
  • Treatment intensification, including lowering target IOP, is indicated when disease status or risk changes.

Conclusions:

  • Glaucoma management is a dynamic process requiring adjustments based on disease progression and risk assessment.
  • Intervention to reduce IOP is crucial when disease status or risk factors indicate potential for further visual loss.
  • Personalized, adaptive treatment strategies are key to preserving vision in glaucoma patients.